by Raynovich Rod | Jul 29, 2014 | 2024 Rayno Biopharmaceuticals Portfolio
Some Huge Moves Today Brings Hope For Summer Rally ETFs Up: FBT $83 up 2.58%, IBB $254.78 up 1.14%, XBI $148.9 up 3.28%. Rayno Large Cap Portfolio: up 14,4% YTD with Biogen Idec(BIIB) and Gilead (GILD) leaders; near July highs. Virtually everything is up but big...
by Raynovich Rod | Jul 22, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, Macro
Update 7/23 Biogen Idec (BIIB) Soars 11% on Earnings EPS at $3.49 vs est $2.83; Sales of MS drugs were $2.42B vs $1.72B last year. Our large cap portfolio is now up 15% YTD with less risk than mid and small caps. One analyst thinks PBYI will be acquired but watch out...
by Raynovich Rod | Jun 30, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Rayno Life Science Stocks Focused on Genetic Tests and Biomarkers We have been writing about molecular diagnostics and tools stocks for over 5 years. Here is the summary of our Portfolio. Yesterday we provided an update from BIO 2014 on personalized medicine and...
by Raynovich Rod | Jun 26, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools
Challenges Ahead But Sequencing Is A Driver We first reported on Personalized Medicine in 2010 with an article on the importance of Biomarkers for exploiting breakthroughs in the molecular basis of disease. The BIO 2014 Personalized Medicine and Diagnostics Forum...
by Raynovich Rod | May 22, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
Update 11/24/14 Clinical Diagnostics and Tools Stocks Review Performance YTD and compared to 11/13 YTD Top winners YTD are: EXAS 104%, ILMN 71.4%, ABAX 36.8% Top Losers YTD are: NSTG 16.6%, RGDX 54%, VRML 30.9% but all were good trades. IWM at $117.4 See Performance...
by Raynovich Rod | May 20, 2014 | 2024 Rayno Biopharmaceuticals Portfolio
Rayno Life Science Focus Stocks: ARIA, IMGN, PCYC Ariad (ARIA) Abstracts Several data presentations will be made for Iclusig (Ponatinib) for leukemias and AP26113 its investigational oral inhibitor of anaplastic lymphoma kinase (ALK). A breakfast meeting featuring...
by Raynovich Rod | Apr 22, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Rayno Life Science Stocks -Green Screen Rules-NASDAQ (4168) Up 1.16% Speculative ETF XBI (134.50) up 4.69% and 7.88% over 5 days; 52 week high $172.52. ETF PBE ($40.85) up over 3%. Momentum stocks are soaring but way off all time highs in February. Big Rayno...
by Raynovich Rod | Apr 11, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Top Ten Reasons For Biotech Correction NASDAQ at 4022,IBB at 221 A Sentiment Driven Market We have been writing about the bull market in biotech stocks since its inception in March 2009 when quality companies were advancing their pipelines and new products in...
by Raynovich Rod | Apr 8, 2014 | 2024 Rayno Biopharmaceuticals Portfolio
NASDAQ Up 0.37% to 4133 Green screen alert with large cap biotechs. Time to cover hedges. Alexion (ALXN) up 2.23% Biogen (BIIB) Up 2.4% Celgene (CELG) up 3.61% Clovis Oncology (CLVS) up 2.85% Gilead (GILD) up 1.35% IBB up 1.96% Regeneron (REGN) up 3.99% Key Trends To...
by Raynovich Rod | Mar 31, 2014 | Biopharmaceuticals
Large Cap Biopharmaceutical Growth Stocks With the MoMo days over the next earnings cycle (Q1,Q2 2014) should give us better clarity on winners for 2014.On the last day of March all of these large caps rallied after a severe one week correction from 3/21-28. Watch...